News Biogen and AbbVie Voluntarily Withdraw Marketing Authorizations for MS Therapy Zinbryta Biogen and AbbVie Voluntarily Withdraw Marketing Authorizations for MS Therapy Zinbryta by Jose Marques Lopes, PhD | March 6, 2018 Share this article: Share article via email Copy article link BiogenĀ and AbbVieĀ have voluntarily withdrawn global marketing authorizations for theirĀ relapsing multiple sclerosisĀ therapyĀ Zinbryta (daclizumab) because of serious side effects that include brain inflammation. The Europe Medicine Agency, which oversees medications across the European Union, also released a statement recommending a “immediate suspension” of Zinbryta’s use by patients and a recall. Twelve cases of brain inflammation worldwide may be linked to the medication’s use based on a preliminary review of data, the EMA states. These include cases ofĀ encephalitis and meningoencephalitis, or inflammation of the three membranes enveloping the brain and spinal cord. Three people have died. āBiogen believes the voluntary worldwide withdrawal of Zinbryta,Ā a treatment for relapsing multiple sclerosis, is in the best interest of patients,ā Alfred Sandrock, Biogen’s executive vice president and chief medical officer, said in a press release. āBiogen and AbbVie continue to prioritize patient safety and the care of multiple sclerosis patients worldwide,ā Sandrock added. Given the limited number of patients still receiving the treatment, the companies also said that it’s no longer possible to continue developing a risk-benefit profile for Zinbryta. Biogen said it will work with regulatory authorities to withdraw Zinbryta and with healthcare providers to support patients who have been affected. The company said it advises patients who are still taking Zinbryta to contact theirĀ healthcare provider with questions or concerns. Zinbryta is used to treat adults with relapsing forms of MS. Due to its risks, the medication is normally given to patients who have tried two or more MS treatments without success. The therapy is an antibody engineered to reduce inflammation. It targets MS patientsā T-cells, which are key immune cells in inflammation. The treatment has been approved in the U.S., the E.U., Canada, England, Wales, Scotland, Switzerland, and Australia. Zinbryta carries a warning on its label about the potential of patients developing a liver injury that could be life-threatening. It advises doctors who prescribe the treatment to keep a close watch on patients’ liver function. In 2017, the European Medicines Agency restricted the use of Zinbryta to patients who had failed to respond to other MS treatments and those with a rapidly evolving disease who were unable to take other disease-modifying medications. The decision followed reports of patients experiencing severe liver damage and one dying of liver disease. Print This Page About the Author Jose Marques Lopes, PhD JosĆ© holds a PhD in neuroscience from the University of Porto, Portugal. After postdocs at Weill Connell Medicine and Western University, where he studied the processes driving hypertension and Alzheimerās disease, he moved on in 2016 to a career in science writing and communication. JosĆ© is the author of several peer-reviewed papers and a book chapter and has presented his research in numerous international meetings. Tags AbbVie, adverse events, Biogen, Daclizumab, relapsing MS, ZINBRYTA
May 2, 2024 News by Marisa Wexler, MS Immigrants to Canada see MS risk rising with time in country: Study
April 30, 2024 News by Andrea Lobo, PhD Committee favors approval of under-the-skin Ocrevus in Europe